MRNS Stock Recent News
MRNS LATEST HEADLINES
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=87485&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=87483&wire=1 or contact Joseph E. Levi, Esq.
Shareholders with losses of $100,000 or more are encouraged to contact the firm. LOS ANGELES , June 25, 2024 /PRNewswire/ -- The Law Offices of Frank R.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=87464&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=87463&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
LOS ANGELES , June 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 5, 2024.
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders with losses of $100,000 or more are encouraged to contact the firm. Shareholders with losses of $100,000 or more are encouraged to contact the firm.